{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:45:55Z","timestamp":1782805555828,"version":"3.54.5"},"reference-count":73,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neuronal ceroid lipofuscinosis or Batten disease comprises a category of autosomal recessive neurodegenerative disorders that primarily affect children. Mutations in different genes lead to different forms of neuronal ceroid lipofuscinoses (CLN1-14). At present, there is no established therapy to cure most of the neuronal ceroid lipofuscinoses and the treatments are symptomatic. Enzyme replacement therapy, gene therapy, stem cell transplantation, and pharmacological chaperone therapy are being tested in different animal models and human patients. Peroxisome proliferator-activated receptor alpha (PPAR\u03b1) is a member of the nuclear hormone receptor superfamily, which along with its transcription partner retinoid X receptor alpha (RXR\u03b1) regulates the expression of their target genes. This review highlights the potential role of PPAR\u03b1 and RXR\u03b1 in the regulation of\n                    <jats:italic>CLN<\/jats:italic>\n                    genes. Here, using the MatInspector program of the Genomatix software, we performed promoter analyses of all\n                    <jats:italic>CLN<\/jats:italic>\n                    genes and observed that most of the\n                    <jats:italic>CLN<\/jats:italic>\n                    genes harbor one or more potential binding sites for PPAR and RXR in their promoter region. We further grouped them according to a binding prediction of the transcription factors to indicate high affinity binding of PPAR to\n                    <jats:italic>CLN2<\/jats:italic>\n                    ,\n                    <jats:italic>CLN3<\/jats:italic>\n                    ,\n                    <jats:italic>CLN4<\/jats:italic>\n                    ,\n                    <jats:italic>CLN5, CLN7<\/jats:italic>\n                    ,\n                    <jats:italic>CLN10<\/jats:italic>\n                    ,\n                    <jats:italic>CLN11<\/jats:italic>\n                    ,\n                    <jats:italic>CLN12<\/jats:italic>\n                    , and\n                    <jats:italic>CLN14<\/jats:italic>\n                    . On the other hand, we observed high affinity binding of RXR to\n                    <jats:italic>CLN1<\/jats:italic>\n                    ,\n                    <jats:italic>CLN3<\/jats:italic>\n                    ,\n                    <jats:italic>CLN6<\/jats:italic>\n                    ,\n                    <jats:italic>CLN7<\/jats:italic>\n                    ,\n                    <jats:italic>CLN8<\/jats:italic>\n                    ,\n                    <jats:italic>CLN10<\/jats:italic>\n                    , and\n                    <jats:italic>CLN13<\/jats:italic>\n                    . Since PPAR\u03b1 and RXR\u03b1 have been demonstrated to control the transcription of\n                    <jats:italic>CLN2<\/jats:italic>\n                    gene, our current promoter analysis findings highlight a possible treatment strategy for neuronal ceroid lipofuscinoses using agonists of PPAR\u03b1 and RXR\u03b1.\n                  <\/jats:p>","DOI":"10.1515\/nipt-2026-0005","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:32:57Z","timestamp":1777501977000},"page":"195-203","source":"Crossref","is-referenced-by-count":0,"title":["PPAR\u03b1 and\u00a0RXR\u03b1 in\u00a0the regulation of\u00a0neuronal ceroid lipofuscinosis genes: implications for\u00a0Batten disease therapy"],"prefix":"10.1515","volume":"5","author":[{"given":"Sujyoti","family":"Chandra","sequence":"first","affiliation":[{"name":"Department of Neurological Sciences , Rush University Medical Center , Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalipada","family":"Pahan","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences , Rush University Medical Center , Chicago , IL , USA"},{"name":"Division of Research and Development , Jesse Brown Veterans Affairs Medical Center , Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026063006574737625_j_nipt-2026-0005_ref_001","doi-asserted-by":"crossref","unstructured":"Schulz, A, Kohlschutter, A, Mink, J, Simonati, A, Williams, R. NCL diseases \u2013 clinical perspectives. Biochim Biophys Acta 2013;1832:1801\u20136. https:\/\/doi.org\/10.1016\/j.bbadis.2013.04.008.","DOI":"10.1016\/j.bbadis.2013.04.008"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_002","doi-asserted-by":"crossref","unstructured":"Nita, DA, Mole, SE, Minassian, BA. Neuronal ceroid lipofuscinoses. Epileptic Disord 2016;18:73\u201388. https:\/\/doi.org\/10.1684\/epd.2016.0844.","DOI":"10.1684\/epd.2016.0844"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_003","doi-asserted-by":"crossref","unstructured":"Warrier, V, Vieira, M, Mole, SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 2013;1832:1827\u201330. https:\/\/doi.org\/10.1016\/j.bbadis.2013.03.017.","DOI":"10.1016\/j.bbadis.2013.03.017"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_004","doi-asserted-by":"crossref","unstructured":"Sleat, DE, Gin, RM, Sohar, I, Wisniewski, K, Sklower-Brooks, S, Pullarkat, RK, et al.. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet 1999;64:1511\u201323. https:\/\/doi.org\/10.1086\/302427.","DOI":"10.1086\/302427"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_005","doi-asserted-by":"crossref","unstructured":"Hachiya, Y, Hayashi, M, Kumada, S, Uchiyama, A, Tsuchiya, K, Kurata, K. Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses. Acta Neuropathol 2006;111:168\u201377. https:\/\/doi.org\/10.1007\/s00401-005-0024-x.","DOI":"10.1007\/s00401-005-0024-x"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_006","doi-asserted-by":"crossref","unstructured":"Haltia, M. The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta 2006;1762:850\u20136. https:\/\/doi.org\/10.1016\/j.bbadis.2006.06.010.","DOI":"10.1016\/j.bbadis.2006.06.010"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_007","doi-asserted-by":"crossref","unstructured":"Haltia, M, Goebel, HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta 2013;1832:1795\u2013800. https:\/\/doi.org\/10.1016\/j.bbadis.2012.08.012.","DOI":"10.1016\/j.bbadis.2012.08.012"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_008","doi-asserted-by":"crossref","unstructured":"Haltia, M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol 2003;62:1\u201313. https:\/\/doi.org\/10.1093\/jnen\/62.1.1.","DOI":"10.1093\/jnen\/62.1.1"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_009","doi-asserted-by":"crossref","unstructured":"Sharp, JD, Wheeler, RB, Parker, KA, Gardiner, RM, Williams, RE, Mole, SE. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat 2003;22:35\u201342.","DOI":"10.1002\/humu.10227"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_010","doi-asserted-by":"crossref","unstructured":"Schulz, A, Dhar, S, Rylova, S, Dbaibo, G, Alroy, J, Hagel, C, et al.. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol 2004;56:342\u201350. https:\/\/doi.org\/10.1002\/ana.20187.","DOI":"10.1002\/ana.20187"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_011","doi-asserted-by":"crossref","unstructured":"Williams, RE, Mole, SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 2012;79:183\u201391. https:\/\/doi.org\/10.1212\/wnl.0b013e31825f0547.","DOI":"10.1212\/WNL.0b013e31825f0547"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_012","doi-asserted-by":"crossref","unstructured":"Kollmann, K, Uusi-Rauva, K, Scifo, E, Tyynela, J, Jalanko, A, Braulke, T. Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim Biophys Acta 2013;1832:1866\u201381. https:\/\/doi.org\/10.1016\/j.bbadis.2013.01.019.","DOI":"10.1016\/j.bbadis.2013.01.019"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_013","doi-asserted-by":"crossref","unstructured":"Hobert, JA, Dawson, G. Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future. Biochim Biophys Acta 2006;1762:945\u201353. https:\/\/doi.org\/10.1016\/j.bbadis.2006.08.004.","DOI":"10.1016\/j.bbadis.2006.08.004"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_014","doi-asserted-by":"crossref","unstructured":"Neverman, NJ, Best, HL, Hofmann, SL, Hughes, SM. Experimental therapies in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta 2015;1852:2292\u2013300. https:\/\/doi.org\/10.1016\/j.bbadis.2015.04.026.","DOI":"10.1016\/j.bbadis.2015.04.026"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_015","doi-asserted-by":"crossref","unstructured":"Leinekugel, P, Michel, S, Conzelmann, E, Sandhoff, K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992;88:513\u201323. https:\/\/doi.org\/10.1007\/bf00219337.","DOI":"10.1007\/BF00219337"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_016","doi-asserted-by":"crossref","unstructured":"Schueler, UH, Kolter, T, Kaneski, CR, Zirzow, GC, Sandhoff, K, Brady, RO. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 2004;27:649\u201358. https:\/\/doi.org\/10.1023\/b:boli.0000042959.44318.7c.","DOI":"10.1023\/B:BOLI.0000042959.44318.7c"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_017","doi-asserted-by":"crossref","unstructured":"Chang, M, Cooper, JD, Sleat, DE, Cheng, SH, Dodge, JC, Passini, MA, et al.. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2008;16:649\u201356. https:\/\/doi.org\/10.1038\/sj.mt.6300415.","DOI":"10.1038\/mt.2008.9"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_018","doi-asserted-by":"crossref","unstructured":"Vuillemenot, BR, Katz, ML, Coates, JR, Kennedy, D, Tiger, P, Kanazono, S, et al.. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol Genet Metabol 2011;104:325\u201337. https:\/\/doi.org\/10.1016\/j.ymgme.2011.06.018.","DOI":"10.1016\/j.ymgme.2011.06.018"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_019","doi-asserted-by":"crossref","unstructured":"Xu, S, Wang, L, El-Banna, M, Sohar, I, Sleat, DE, Lobel, P. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2011;19:1842\u20138. https:\/\/doi.org\/10.1038\/mt.2011.130.","DOI":"10.1038\/mt.2011.130"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_020","doi-asserted-by":"crossref","unstructured":"Sondhi, D, Hackett, NR, Peterson, DA, Stratton, J, Baad, M, Travis, KM, et al.. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007;15:481\u201391. https:\/\/doi.org\/10.1038\/sj.mt.6300049.","DOI":"10.1038\/sj.mt.6300049"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_021","doi-asserted-by":"crossref","unstructured":"Sondhi, D, Peterson, DA, Edelstein, AM, del Fierro, K, Hackett, NR, Crystal, RG. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp Neurol 2008;213:18\u201327. https:\/\/doi.org\/10.1016\/j.expneurol.2008.04.022.","DOI":"10.1016\/j.expneurol.2008.04.022"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_022","doi-asserted-by":"crossref","unstructured":"Cabrera-Salazar, MA, Roskelley, EM, Bu, J, Hodges, BL, Yew, N, Dodge, JC, et al.. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther 2007;15:1782\u20138. https:\/\/doi.org\/10.1038\/sj.mt.6300249.","DOI":"10.1038\/sj.mt.6300249"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_023","doi-asserted-by":"crossref","unstructured":"Hackett, NR, Redmond, DE, Sondhi, D, Giannaris, EL, Vassallo, E, Stratton, J, et al.. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Hum Gene Ther 2005;16:1484\u2013503. https:\/\/doi.org\/10.1089\/hum.2005.16.1484.","DOI":"10.1089\/hum.2005.16.1484"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_024","doi-asserted-by":"crossref","unstructured":"Worgall, S, Sondhi, D, Hackett, NR, Kosofsky, B, Kekatpure, MV, Neyzi, N, et al.. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19:463\u201374. https:\/\/doi.org\/10.1089\/hum.2008.022.","DOI":"10.1089\/hum.2008.022"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_025","doi-asserted-by":"crossref","unstructured":"Selden, NR, Al-Uzri, A, Huhn, SL, Koch, TK, Sikora, DM, Nguyen-Driver, MD, et al.. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr 2013;11:643\u201352. https:\/\/doi.org\/10.3171\/2013.3.peds12397.","DOI":"10.3171\/2013.3.PEDS12397"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_026","doi-asserted-by":"crossref","unstructured":"Schulz, A, Ajayi, T, Specchio, N, de Los Reyes, E, Gissen, P, Ballon, D, et al.. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018;378:1898\u2013907. https:\/\/doi.org\/10.1056\/nejmoa1712649.","DOI":"10.1056\/NEJMoa1712649"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_027","doi-asserted-by":"crossref","unstructured":"Sondhi, D, Hackett, NR, Apblett, RL, Kaminsky, SM, Pergolizzi, RG, Crystal, RG. Feasibility of gene therapy for late neuronal ceroid lipofuscinosis. Arch Neurol 2001;58:1793\u20138. https:\/\/doi.org\/10.1001\/archneur.58.11.1793.","DOI":"10.1001\/archneur.58.11.1793"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_028","doi-asserted-by":"crossref","unstructured":"Walus, M, Kida, E, Golabek, AA. Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I. Hum Mutat 2010;31:710\u201321. https:\/\/doi.org\/10.1002\/humu.21251.","DOI":"10.1002\/humu.21251"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_029","doi-asserted-by":"crossref","unstructured":"Kummer, MP, Heneka, MT. PPARs in Alzheimer\u2019s disease. PPAR Res 2008;2008:403896. https:\/\/doi.org\/10.1155\/2008\/403896.","DOI":"10.1155\/2008\/403896"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_030","doi-asserted-by":"crossref","unstructured":"Viswakarma, N, Jia, Y, Bai, L, Vluggens, A, Borensztajn, J, Xu, J, et al.. Coactivators in PPAR-regulated gene expression. PPAR Res 2010;2010. https:\/\/doi.org\/10.1155\/2010\/250126.","DOI":"10.1155\/2010\/250126"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_031","doi-asserted-by":"crossref","unstructured":"Roy, A, Jana, M, Corbett, GT, Ramaswamy, S, Kordower, JH, Gonzalez, FJ, et al.. Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor alpha. Cell Rep 2013;4:724\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2013.07.028.","DOI":"10.1016\/j.celrep.2013.07.028"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_032","doi-asserted-by":"crossref","unstructured":"Roy, A, Pahan, K. PPARalpha signaling in the hippocampus: crosstalk between fat and memory. J Neuroimmune Pharmacol 2015;10:30\u20134. https:\/\/doi.org\/10.1007\/s11481-014-9582-9.","DOI":"10.1007\/s11481-014-9582-9"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_033","doi-asserted-by":"crossref","unstructured":"Zoete, V, Grosdidier, A, Michielin, O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007;1771:915\u201325. https:\/\/doi.org\/10.1016\/j.bbalip.2007.01.007.","DOI":"10.1016\/j.bbalip.2007.01.007"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_034","doi-asserted-by":"crossref","unstructured":"Desvergne, B, Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649\u201388. https:\/\/doi.org\/10.1210\/edrv.20.5.0380.","DOI":"10.1210\/edrv.20.5.0380"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_035","doi-asserted-by":"crossref","unstructured":"Nagy, L, Kao, HY, Chakravarti, D, Lin, RJ, Hassig, CA, Ayer, DE, et al.. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89:373\u201380. https:\/\/doi.org\/10.1016\/s0092-8674(00)80218-4.","DOI":"10.1016\/S0092-8674(00)80218-4"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_036","doi-asserted-by":"crossref","unstructured":"Chen, JD, Evans, RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454\u20137. https:\/\/doi.org\/10.1038\/377454a0.","DOI":"10.1038\/377454a0"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_037","doi-asserted-by":"crossref","unstructured":"Karagianni, P, Wong, J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007;26:5439\u201349. https:\/\/doi.org\/10.1038\/sj.onc.1210612.","DOI":"10.1038\/sj.onc.1210612"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_038","doi-asserted-by":"crossref","unstructured":"Varanasi, U, Chu, R, Huang, Q, Castellon, R, Yeldandi, AV, Reddy, JK. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1996;271:2147\u201355. https:\/\/doi.org\/10.1074\/jbc.271.4.2147.","DOI":"10.1074\/jbc.271.4.2147"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_039","doi-asserted-by":"crossref","unstructured":"Tetel, MJ, Auger, AP, Charlier, TD. Who\u2019s in charge? Nuclear receptor coactivator and corepressor function in brain and behavior. Front Neuroendocrinol 2009;30:328\u201342. https:\/\/doi.org\/10.1016\/j.yfrne.2009.04.008.","DOI":"10.1016\/j.yfrne.2009.04.008"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_040","doi-asserted-by":"crossref","unstructured":"Kwok, RP, Lundblad, JR, Chrivia, JC, Richards, JP, Bachinger, HP, Brennan, RG, et al.. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994;370:223\u20136. https:\/\/doi.org\/10.1038\/370223a0.","DOI":"10.1038\/370223a0"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_041","doi-asserted-by":"crossref","unstructured":"Chakravarti, D, LaMorte, VJ, Nelson, MC, Nakajima, T, Schulman, IG, Juguilon, H, et al.. Role of CBP\/P300 in nuclear receptor signalling. Nature 1996;383:99\u2013103. https:\/\/doi.org\/10.1038\/383099a0.","DOI":"10.1038\/383099a0"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_042","doi-asserted-by":"crossref","unstructured":"Goodman, RH, Smolik, S. CBP\/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553\u201377. https:\/\/doi.org\/10.1101\/gad.14.13.1553.","DOI":"10.1101\/gad.14.13.1553"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_043","doi-asserted-by":"crossref","unstructured":"Wang, Z, Qi, C, Krones, A, Woodring, P, Zhu, X, Reddy, JK, et al.. Critical roles of the p160 transcriptional coactivators p\/CIP and SRC-1 in energy balance. Cell Metab 2006;3:111\u201322. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.002.","DOI":"10.1016\/j.cmet.2006.01.002"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_044","doi-asserted-by":"crossref","unstructured":"Onate, SA, Tsai, SY, Tsai, MJ, O\u2019Malley, BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354\u20137. https:\/\/doi.org\/10.1126\/science.270.5240.1354.","DOI":"10.1126\/science.270.5240.1354"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_045","unstructured":"Zhu, Y, Qi, C, Calandra, C, Rao, MS, Reddy, JK. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr 1996;6:185\u201395."},{"key":"2026063006574737625_j_nipt-2026-0005_ref_046","doi-asserted-by":"crossref","unstructured":"Puigserver, P, Wu, Z, Park, CW, Graves, R, Wright, M, Spiegelman, BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829\u201339. https:\/\/doi.org\/10.1016\/s0092-8674(00)81410-5.","DOI":"10.1016\/S0092-8674(00)81410-5"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_047","doi-asserted-by":"crossref","unstructured":"Lin, J, Puigserver, P, Donovan, J, Tarr, P, Spiegelman, BM. Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem 2002;277:1645\u20138. https:\/\/doi.org\/10.1074\/jbc.c100631200.","DOI":"10.1074\/jbc.C100631200"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_048","doi-asserted-by":"crossref","unstructured":"Becker, PB, Horz, W. ATP-dependent nucleosome remodeling. Annu Rev Biochem 2002;71:247\u201373. https:\/\/doi.org\/10.1146\/annurev.biochem.71.110601.135400.","DOI":"10.1146\/annurev.biochem.71.110601.135400"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_049","doi-asserted-by":"crossref","unstructured":"Tang, L, Nogales, E, Ciferri, C. Structure and function of SWI\/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog Biophys Mol Biol 2010;102:122\u20138. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2010.05.001.","DOI":"10.1016\/j.pbiomolbio.2010.05.001"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_050","doi-asserted-by":"crossref","unstructured":"Surapureddi, S, Yu, S, Bu, H, Hashimoto, T, Yeldandi, AV, Kashireddy, P, et al.. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci USA 2002;99:11836\u201341. https:\/\/doi.org\/10.1073\/pnas.182426699.","DOI":"10.1073\/pnas.182426699"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_051","doi-asserted-by":"crossref","unstructured":"Surapureddi, S, Viswakarma, N, Yu, S, Guo, D, Rao, MS, Reddy, JK. PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex. Biochem Biophys Res Commun 2006;343:535\u201343. https:\/\/doi.org\/10.1016\/j.bbrc.2006.02.160.","DOI":"10.1016\/j.bbrc.2006.02.160"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_052","doi-asserted-by":"crossref","unstructured":"Heneka, MT, Landreth, GE. PPARs in the brain. Biochim Biophys Acta 2007;1771:1031\u201345. https:\/\/doi.org\/10.1016\/j.bbalip.2007.04.016.","DOI":"10.1016\/j.bbalip.2007.04.016"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_053","doi-asserted-by":"crossref","unstructured":"Heneka, MT, Reyes-Irisarri, E, Hull, M, Kummer, MP. Impact and therapeutic potential of PPARs in Alzheimer\u2019s disease. Curr Neuropharmacol 2011;9:643\u201350. https:\/\/doi.org\/10.2174\/157015911798376325.","DOI":"10.2174\/157015911798376325"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_054","doi-asserted-by":"crossref","unstructured":"Chandra, S, Pahan, K. Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer\u2019s disease via peroxisome proliferator-activated receptor alpha. J Alzheimers Dis Rep 2019;3:149\u201368. https:\/\/doi.org\/10.3233\/adr-190104.","DOI":"10.3233\/ADR-190104"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_055","doi-asserted-by":"crossref","unstructured":"Kersten, S, Wahli, W. Peroxisome proliferator activated receptor agonists. EXS 2000;89:141\u201351.","DOI":"10.1007\/978-3-0348-8393-1_9"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_056","doi-asserted-by":"crossref","unstructured":"Motojima, K. Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions. Cell Struct Funct 1993;18:267\u201377. https:\/\/doi.org\/10.1247\/csf.18.267.","DOI":"10.1247\/csf.18.267"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_057","doi-asserted-by":"crossref","unstructured":"Roy, A, Pahan, K. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol 2009;31:339\u201351. https:\/\/doi.org\/10.1080\/08923970902785253.","DOI":"10.1080\/08923970902785253"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_058","doi-asserted-by":"crossref","unstructured":"Ghosh, A, Corbett, GT, Gonzalez, FJ, Pahan, K. Gemfibrozil and fenofibrate, food and drug administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor alpha: implications for late infantile Batten disease therapy. J Biol Chem 2012;287:38922\u201335. https:\/\/doi.org\/10.1074\/jbc.m112.365148.","DOI":"10.1074\/jbc.M112.365148"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_059","doi-asserted-by":"crossref","unstructured":"Cartharius, K, Frech, K, Grote, K, Klocke, B, Haltmeier, M, Klingenhoff, A, et al.. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933\u201342. https:\/\/doi.org\/10.1093\/bioinformatics\/bti473.","DOI":"10.1093\/bioinformatics\/bti473"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_060","doi-asserted-by":"crossref","unstructured":"Ghosh, A, Jana, M, Modi, K, Gonzalez, FJ, Sims, KB, Berry-Kravis, E, et al.. Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J Biol Chem 2015;290:10309\u201324. https:\/\/doi.org\/10.1074\/jbc.m114.610659.","DOI":"10.1074\/jbc.M114.610659"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_061","doi-asserted-by":"crossref","unstructured":"Ghosh, A, Rangasamy, SB, Modi, KK, Pahan, K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem 2017;141:423\u201335. https:\/\/doi.org\/10.1111\/jnc.13987.","DOI":"10.1111\/jnc.13987"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_062","doi-asserted-by":"crossref","unstructured":"Roy, A, Jana, M, Kundu, M, Corbett, GT, Rangaswamy, SB, Mishra, RK, et al.. HMG-CoA reductase inhibitors bind to PPARalpha to upregulate neurotrophin expression in the brain and improve memory in mice. Cell Metab 2015;22:253\u201365. https:\/\/doi.org\/10.1016\/j.cmet.2015.05.022.","DOI":"10.1016\/j.cmet.2015.05.022"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_063","doi-asserted-by":"crossref","unstructured":"Patel, D, Roy, A, Kundu, M, Jana, M, Luan, CH, Gonzalez, FJ, et al.. Aspirin binds to PPARalpha to stimulate hippocampal plasticity and protect memory. Proc Natl Acad Sci U S A 2018;115:E7408\u201317.","DOI":"10.1073\/pnas.1802021115"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_064","doi-asserted-by":"crossref","unstructured":"Chandra, S, Jana, M, Pahan, K. Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer\u2019s disease via PPARalpha. J Neurosci 2018;38:6682\u201399. https:\/\/doi.org\/10.1523\/jneurosci.0054-18.2018.","DOI":"10.1523\/JNEUROSCI.0054-18.2018"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_065","doi-asserted-by":"crossref","unstructured":"Chandra, S, Roy, A, Patel, DR, Pahan, K. PPARalpha between aspirin and plaque clearance. J Alzheimers Dis 2019;71:389\u201397. https:\/\/doi.org\/10.3233\/jad-190586.","DOI":"10.3233\/JAD-190586"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_066","doi-asserted-by":"crossref","unstructured":"Chandra, S, Roy, A, Jana, M, Pahan, K. Cinnamic acid activates PPARalpha to stimulate lysosomal biogenesis and lower amyloid plaque pathology in an Alzheimer\u2019s disease mouse model. Neurobiol Dis 2019;124:379\u201395. https:\/\/doi.org\/10.1016\/j.nbd.2018.12.007.","DOI":"10.1016\/j.nbd.2018.12.007"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_067","doi-asserted-by":"crossref","unstructured":"Dawson, MI, Xia, Z. The retinoid X receptors and their ligands. Biochim Biophys Acta 2012;1821:21\u201356. https:\/\/doi.org\/10.1016\/j.bbalip.2011.09.014.","DOI":"10.1016\/j.bbalip.2011.09.014"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_068","doi-asserted-by":"crossref","unstructured":"Sleat, DE, El-Banna, M, Sohar, I, Kim, KH, Dobrenis, K, Walkley, SU, et al.. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. Mol Genet Metabol 2008;94:222\u201333. https:\/\/doi.org\/10.1016\/j.ymgme.2008.01.014.","DOI":"10.1016\/j.ymgme.2008.01.014"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_069","doi-asserted-by":"crossref","unstructured":"Viglio, S, Marchi, E, Wisniewski, K, Casado, B, Cetta, G, Iadarola, P. Diagnosis of late-infantile neuronal ceroid lipofuscinosis: a new sensitive method to assay lysosomal pepstatin-insensitive proteinase activity in human and animal specimens by capillary electrophoresis. Electrophoresis 2001;22:2343\u201350. https:\/\/doi.org\/10.1002\/1522-2683(20017)22:11<2343::aid-elps2343>3.0.co;2-2.","DOI":"10.1002\/1522-2683(20017)22:11<2343::AID-ELPS2343>3.0.CO;2-2"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_070","doi-asserted-by":"crossref","unstructured":"Kim, K, Kleinman, HK, Lee, HJ, Pahan, K. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis 2017;12:113. https:\/\/doi.org\/10.1186\/s13023-017-0663-8.","DOI":"10.1186\/s13023-017-0663-8"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_071","unstructured":"Buyukcelik, M, Anarat, A, Bayazit, AK, Noyan, A, Ozel, A, Anarat, R, et al.. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 2002;44:40\u20134."},{"key":"2026063006574737625_j_nipt-2026-0005_ref_072","doi-asserted-by":"crossref","unstructured":"Smalley, CM, Goldberg, SJ. A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol 2008;2:106\u201311. https:\/\/doi.org\/10.1016\/j.jacl.2008.02.003.","DOI":"10.1016\/j.jacl.2008.02.003"},{"key":"2026063006574737625_j_nipt-2026-0005_ref_073","doi-asserted-by":"crossref","unstructured":"Jana, M, Dutta, D, Poddar, J, Pahan, K. Activation of PPARalpha exhibits therapeutic efficacy in a mouse model of juvenile neuronal ceroid lipofuscinosis. J Neurosci 2023;43:1814\u201329. https:\/\/doi.org\/10.1523\/jneurosci.2447-21.2023.","DOI":"10.1523\/JNEUROSCI.2447-21.2023"}],"container-title":["NeuroImmune Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/nipt-2026-0005\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/nipt-2026-0005\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:12:22Z","timestamp":1782803542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/nipt-2026-0005\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,6,24]]}},"alternative-id":["10.1515\/nipt-2026-0005"],"URL":"https:\/\/doi.org\/10.1515\/nipt-2026-0005","relation":{},"ISSN":["2750-6665"],"issn-type":[{"value":"2750-6665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}